Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms

被引：0
|
作者：
Rui-Xia Xu
Jun Liu
Xiao-Lin Li
Sha Li
Yan Zhang
Yan-Jun Jia
Jing Sun
Jian-Jun Li
机构：
[1] FuWai Hospital,Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease
[2] National Center for Cardiovascular Disease,undefined
[3] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Translational Medicine | / 13卷
关键词：
Ezetimibe; PCSK9; Liver; Intestine; Kidney; Molecular mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
    Blanco-Ruiz, Marina
    Amaya-Pascasio, Laura
    de Torres Chacon, Reyes
    Josefa Alvarez Soria, Maria
    Arjona-Padillo, Antonio
    Carrillo Bailen, Maria Magdalena
    Milan Pinilla, Rodrigo
    Perez Ortega, Irene
    Sanchez Rodriguez, Belen
    Andrade Zumarraga, Luis
    Valverde Moyano, Roberto
    Payan Ortiz, Manuel
    Castillo Fernandez, Alba Maria
    Del Toro Perez, Cristina
    Gonzalez Bustos, Pablo
    Aguera Morales, Eduardo
    Sanchez Lopez, Purificacion
    Hidalgo Martin, Beatriz
    Roa Chamorro, Ricardo
    Fernandez Perez, Javier
    Mejias Olmedo, Maria Victoria
    Martinez-Sanchez, Patricia
    ATHEROSCLEROSIS PLUS, 2021, 45 : 32 - 38
  • [22] Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
    Zhang, Shengxuan
    Sun, Lei
    Xu, Xinyu
    Zhang, Yanling
    Chen, Qilan
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01):
  • [23] PCSK9 with a gain of function D374Y mutation aggravates atherosclerosis by inhibiting PPARα expression
    Cui, Yuan feng
    Chen, Xiao cui
    Mijiti, Tuoluonayi
    Abudurusuli, Abidan
    Deng, Li hui
    Ma, Xiang
    Chen, Bangdang
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters
    Wu, Minhao
    Dong, Bin
    Cao, Aiqin
    Li, Hai
    Liu, Jingwen
    ATHEROSCLEROSIS, 2012, 224 (02) : 401 - 410
  • [25] Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?
    Liu, Qiong
    Guo, Yuan
    Gui, Ya-jun
    Liao, Cai-xiu
    Xu, Dan-yan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 361 - 362
  • [26] Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9
    Kamada, Yoshihiro
    Yamamoto, Akiko
    Fujiyoshi, Anna
    Koseki, Masahiro
    Morishita, Koichi
    Asuka, Tatsuya
    Takamatsu, Shinji
    Sakata, Yasushi
    Takehara, Tetsuo
    Taniguchi, Naoyuki
    Miyoshi, Eiji
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (03) : 682 - 688
  • [27] Exercise training increased gene expression of LDL-R and PCSK9 in intestine: link to transintestinal cholesterol excretion
    Farahnak, Zahra
    Chapados, Natalie
    Lavoie, Jean-Marc
    GENERAL PHYSIOLOGY AND BIOPHYSICS, 2018, 37 (03) : 309 - 317
  • [28] Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1
    Ferri, Nicola
    Marchiano, Silvia
    Lupo, Maria Giovanna
    Trenti, Annalisa
    Biondo, Giuseppe
    Castaldello, Paola
    Corsini, Alberto
    PHARMACOLOGICAL RESEARCH, 2017, 122 : 96 - 104
  • [29] A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels
    Groves, Carl
    Shetty, Chandrashekar
    Strange, Richard C.
    Waldron, Julian
    Ramachandran, Sudarshan
    POSTGRADUATE MEDICAL JOURNAL, 2017, 93 (1098) : 205 - 208
  • [30] Effect of PCSK9 Monoclonal Antibody Versus Placebo/Ezetimibe on Atrial Fibrillation in Patients at High Cardiovascular Risk: A Meta-Analysis of 26 Randomized Controlled Trials
    Yang, Shuai
    Shen, Wen
    Zhang, Hong-Zhou
    Wang, Chen-Xi
    Yang, Ping-Ping
    Wu, Qing-Hua
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (05) : 927 - 940
12345